BRWA
MRKR icon

B. Riley Wealth Advisors’s Marker Therapeutics MRKR Stock Holding History

B. Riley Wealth Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,260
Closed -$231K – 1442
2021
Q2 		$231K Buy
+8,260
New +$217K 0.01% 1155

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

B. Riley Wealth Advisors's MRKR Position: Q3 2021 in Review

B. Riley Wealth Advisors sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 8,260 shares — an estimated $231K sold.

B. Riley Wealth Advisors first reported a position in MRKR in Q2 2021 and held it in 1 quarter. The position peaked at $231K in Q2 2021. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

  • B. Riley Wealth Advisors reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 8,260 Marker Therapeutics shares in Q3 2021, an estimated $231K.
  • B. Riley Wealth Advisors first reported a position in Marker Therapeutics in Q2 2021 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Marker Therapeutics position peaked at $231K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.